<|begin_of_text|><|start_header_id|>system<|end_header_id|>

You are an expert at identifying data availability statements in scientific text. A data availability statement describes where research data can be found or how it can be accessed.<|eot_id|><|start_header_id|>user<|end_header_id|>

Determine if the following text contains a data availability statement. Answer with 'yes' or 'no'.

Text: Data that support the findings of this study have been deposited in the Gene Expression Omnibus (GEO) under accession codes GSE65458 (Microarrays), GSE68248 (RNA-seq) and GSE66543 (ChIP-seq). The proteomics data were deposited in the PRIDE repository under accession code PXD001673 (file Dawid1.zip contains the MDA-MB-231 siRNA TP53 experiment: A1-4 are 4 replicates of siRNA TP53 condition; B1-4 are 4 replicates of siControl condition, File Dawid2.zip contains the MDA-MB-231 siRNA PSMA2 experiment: A1-4 are 4 replicates of siRNA PSMA2 condition; B1-4 are 4 replicates of siControl condition). Source data for Fig. 1 and Supplementary Fig. 1 (gene/protein signatures, proteomics, transcriptomics, ChIP-seq peaks, pathway analysis, proteasome transcription validation) have been provided as Supplementary Tables 1-5, 9 and 13. Source data for Fig. 3b and Supplementary Fig. 3d (human tumor samples) have been provided as Supplementary Table 15. Source data for Fig. 4 and Supplementary Fig. 4 (ChIP validation, TF identification) have been provided as Supplementary Tables 4 and 6. Source data for Fig. 6 and Supplementary Fig. 6 (protein signature, proteomics) have been provided as Supplementary Tables 1-2. 
Gene expression data, TP53 mutation status and clinical annotation for Breast Invasive Carcinoma, Bladder Carcinoma, Lung Adenocarcinoma, Head and Neck Carcinoma, Colorectal Adenocarcinoma, Urothelial Bladder Cancer, Brain Lower Grade Glioma, Liver Hepatocellular Carcinoma, Squamous Cell Lung Cancer (TCGA datasets) for Fig. 2b, Supplementary Fig. 2d and Supplementary Table 14 have been obtained from Cancer Genomics Data Server using the cgdsr package for R. 
The breast cancer patient survival data for Fig. 2a and Supplementary Fig. 2a, c were derived from a breast cancer meta-dataset composed of 3458 samples associated with the Km-plotter online analysis tool. Expression and clinical data of breast cancer samples in this meta-dataset are obtained from the following datasets: E-MTAB-365, GSE11121, GSE12093, GSE12276, GSE1456, GSE16391, GSE16446, GSE17705, GSE17907, GSE19615, GSE20194, GSE20271, GSE2034, GSE20685, GSE20711, GSE21653, GSE2603, GSE26971, GSE2990, GSE31448, GSE31519, GSE3494, GSE5327, GSE6532, GSE7390, GSE919.
Data used to calculate statistics in Figs. 1d, 3a, c-f; 4d-g; 5d; 6e, h-i; 7b and Supplementary Figs. 1e, 3a-c, e-h; 4c-d; 5d,g; 6a,e,h; 7a-b, d-g are provided in Supplementary Table 10 (Statistics Source Data). All other data supporting the findings of this study are available from the corresponding author upon reasonable request.
Data that support the findings of this study have been deposited in the Gene Expression Omnibus (GEO) under accession codes GSE65458 (Microarrays), GSE68248 (RNA-seq) and GSE66543 (ChIP-seq). The proteomics data were deposited in the PRIDE repository under accession code PXD001673 (file Dawid1.zip contains the MDA-MB-231 siRNA TP53 experiment: A1-4 are 4 replicates of siRNA TP53 condition; B1-4 are 4 replicates of siControl condition, File Dawid2.zip contains the MDA-MB-231 siRNA PSMA2 experiment: A1-4 are 4 replicates of siRNA PSMA2 condition; B1-4 are 4 replicates of siControl condition). Source data for Fig. 1 and Supplementary Fig. 1 (gene/protein signatures, proteomics, transcriptomics, ChIP-seq peaks, pathway analysis, proteasome transcription validation) have been provided as Supplementary Tables 1-5, 9 and 13. Source data for Fig. 3b and Supplementary Fig. 3d (human tumor samples) have been provided as Supplementary Table 15. Source data for Fig. 4 and Supplementary Fig. 4 (ChIP validation, TF identification) have been provided as Supplementary Tables 4 and 6. Source data for Fig. 6 and Supplementary Fig. 6 (protein signature, proteomics) have been provided as Supplementary Tables 1-2. 
Gene expression data, TP53 mutation status and clinical annotation for Breast Invasive Carcinoma, Bladder Carcinoma, Lung Adenocarcinoma, Head and Neck Carcinoma, Colorectal Adenocarcinoma, Urothelial Bladder Cancer, Brain Lower Grade Glioma, Liver Hepatocellular Carcinoma, Squamous Cell Lung Cancer (TCGA datasets) for Fig. 2b, Supplementary Fig. 2d and Supplementary Table 14 have been obtained from Cancer Genomics Data Server using the cgdsr package for R. 
The breast cancer patient survival data for Fig. 2a and Supplementary Fig. 2a, c were derived from a breast cancer meta-dataset composed of 3458 samples associated with the Km-plotter online analysis tool. Expression and clinical data of breast cancer samples in this meta-dataset are obtained from the following datasets: E-MTAB-365, GSE11121, GSE12093, GSE12276, GSE1456, GSE16391, GSE16446, GSE17705, GSE17907, GSE19615, GSE20194, GSE20271, GSE2034, GSE20685, GSE20711, GSE21653, GSE2603, GSE26971, GSE2990, GSE31448, GSE31519, GSE3494, GSE5327, GSE6532, GSE7390, GSE919.
Data used to calculate statistics in Figs. 1d, 3a, c-f; 4d-g; 5d; 6e, h-i; 7b and Supplementary Figs. 1e, 3a-c, e-h; 4c-d; 5d,g; 6a,e,h; 7a-b, d-g are provided in Supplementary Table 10 (Statistics Source Data). All other data supporting the findings of this study are available from the corresponding author upon reasonable request.
<|eot_id|><|start_header_id|>assistant<|end_header_id|>

yes<|eot_id|>